Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy

Andrologia

Volumn 48, Issue 2, 2016, Pages 198-202

  Sumii, K ^a   Miyake, H ^a   Enatsu, N ^a   Matsushita, K ^a   Fujisawa, M ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Health related quality of life; Late onset hypogonadism; Testosterone replacement therapy

Indexed keywords

TESTOSTERONE ENANTATE; ANDROGEN; TESTOSTERONE;

ADULT; AGED; AGING MALE SYMPTOM SCORE; ANDROGEN THERAPY; ARTICLE; CONTROLLED STUDY; HUMAN; HYPOGONADISM; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 8; TREATMENT OUTCOME; COHORT ANALYSIS; HEALTH STATUS; HORMONE SUBSTITUTION; JAPAN; LATE ONSET DISORDER; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; PSYCHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; COHORT STUDIES; HEALTH STATUS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; JAPAN; LATE ONSET DISORDERS; MALE; MENTAL HEALTH; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84957431168     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/and.12433     Document Type: Article

References (27)

1. Amory JK, Watts NB, Easley KA (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510.
2. Bhasiin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559.
3. Cavallini G, Caracciolo S, Vitali G (2004) Carnitine vs. androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63:641-646.
4. Chen RY, Ng KK (2010) Self-referred older Asian males in a men's health clinic: the interrelationships between androgens, metabolic parameters and quality of life measures. Aging Male 13:233-241.
5. Cherrier MM, Matsumoto AM, Amory JK (2005) Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64:2063-2068.
6. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91:3908-3915.
7. Fukuhara S, Suzukamo Y (2004) Manual of the SF-8 Japanese version: Institute for Health Outcomes & Process Evaluation Research, Kyoto, pp 7-12.
8. Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW (2013) Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol 190:187-193.
9. Gauden A, Weir P, Hawthorne G, Kaye A (2011) Systematic review of quality of life in the management of vestibular schwannoma. J Clin Neurosci 18:1573-1584.
10. Haffner SM, Valdez RA, Stern MP, Katz MS (1993) Obesity, body fat distribution and sex hormones in men. Int J Obes 17:643-649.
11. Kapoor D, Goodwin E, Channer KS, Jones TH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endcrinol 154:899-906.
12. Kapoor D, Clarke S, Channer KS, Jones TH (2007) Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 30:500-507.
13. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2002) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:266-272.
14. Lunenfeld B, Saad F, Hoesl CE (2005) ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male 8:59-74.
15. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ (2001) A double-blind, placebo-controlled, randomised clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078-4088.
16. Namiki M, Akaza H, Shimazui T, Ito N, Iwamoto T, Baba K, Kumano H, Koh E, Tsujimura A, Matsumiya K, Horie S, Maruyama O, Marumo K, Yanase T, Kumamoto Y (2008) Clinical practice manual for late-onset hypogonadism syndrome. Int J Urol 15:377-388.
17. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC; International society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU) (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, EAU recommendations. Eur Urol 48:1-4.
18. Okada K, Yamaguchi K, Chiba K, Miyake H, Fujisawa M (2014) Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism. Aging Male 17:72-75.
19. Page ST, Amory JK, Bowman FD (2005) Exogenous testosterone (T) alone or with finasteride increase physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510.
20. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R (2007) Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92:3568-3572.
21. Saad F, Gooren L, Haider A, Yassin A (2007) An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 53:353-357.
22. Traish AM, Guay A, Feeley R, Saad F (2009) The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 30:10-22.
23. Turner-Bowker DM, Bayliss AM, Ware JE Jr, Kosinski M (2003) Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res 12:1003-1012.
24. Wald M, Meacham RB, Ross LS, Niederberger CS (2006) Testosterone replacement therapy for older men. J Androl 27:126-132.
25. Watt T, Cramon P, Frendl DM, Ware JE Jr, ThyQol Group (2014) Assessing health-related quality of life in patients with benign non-toxic goitre. Best Pract Res Clin Endocrinol Metab 28:559-575.
26. Yassin AA, Saad F (2007) Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 4:497-501.
27. Yassin DJ, Doros G, Hammerer PG, Yassin AA (2014) Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 11:1567-1576.